Drugs / Selvigaltin
Selvigaltin
Trials 6 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT07082270 | Apr 2026 → Feb 2028 | plasma cell myeloma | Roswell Park Cancer Institute | Withdrawn | No outcome recorded |
| Phase 1 | NCT03809052 | Jan → Jun 2019 | — | Galecto Biotech AB | Completed | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT05240131 | Mar 2022 → May 2024 | non-small cell lung carcinoma | Galecto Biotech AB | Unknown | No outcome recorded |
| Phase 1/2 | NCT05009680 | Sep 2021 → Jul 2022 | — | Galecto Biotech AB | Unknown | No outcome recorded |
| Phase 1/2 | NCT04607655 | Mar 2021 → Jul 2022 | metabolic dysfunction-associated steatohepatitis | Galecto Biotech AB | Withdrawn | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05913388 | Feb 2024 → Feb 2028 expected | head and neck squamous cell carcinoma, metastatic melanoma | Providence Health & Services | Recruiting | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05747573 Comparator | Jan → Apr 2023 | — | Galecto Biotech AB | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Selvigaltin | “Selvigaltin (GB1211), an orally available small molecule galectin-3 inhibitor developed as a treatment for liver fibrosis and cirrhosis, was evaluated to assess the effect of...” PMID 39358661 ↗ Oct 20242“Relative bioavailability and food effect of the galectin-3 inhibitor selvigaltin (GB1211) administered as a tablet in healthy participants (GALBA-1).” PMID 39167148 ↗ Aug 2024 |
| Known as | GB1211 | “Selvigaltin (GB1211), an orally available small molecule galectin-3 inhibitor developed as a treatment for liver fibrosis and cirrhosis, was evaluated to assess the effect of...” PMID 39358661 ↗ Oct 20245“Relative bioavailability and food effect of the galectin-3 inhibitor selvigaltin (GB1211) administered as a tablet in healthy participants (GALBA-1).” PMID 39167148 ↗ Aug 2024 |
| Known as | Selvigaltina | ChEMBL registry synonym — accepted as the source's own label CHEMBL5182222 ↗ |
| Known as | Selvigaltine | ChEMBL registry synonym — accepted as the source's own label CHEMBL5182222 ↗ |
| Action | Inhibit | “GB1211 is an orally bioavailable galectin-3 inhibitor, developed to be systemically active.” PMID 36914828 ↗ Mar 2023 |
| Modality | Small molecule | “orally available small molecule” NCT04607655 ↗ |
| Route | Oral | “This phase 1, double-blind, placebo-controlled, first-in-human study (NCT03809052) included a single ascending-dose phase (with a food-effect cohort) where participants across...” PMID 36914828 ↗ Mar 2023 |